Open Nav

Please submit your session questions in advance at

Isaac Bright


RubrYc Therapeutics, Inc.

Dr. Bright is an entrepreneurial physician with a robust track-record building shareholder value and delivering transactional success for more than a decade. Isaac started as Financial Analyst at CIBC World Markets in 2004, and was a Howard E. Mitchell Fellow, earning his MBA at The Wharton School between 2004-2006. Isaac Joined the Medtronic Corporate Development team in 2006, and quickly progressed, becoming Director of Business Development for Medtronic Neuromodulation in 2008. Dr. Bright joined the leadership team of QuantaLife, Inc. in 2009 and drove the Company’s financing and strategic transaction initiatives through the successful trade-sale to Bio-Rad Laboratories in 2011. Dr. Bright spent more than 4 years serving as the only American Partner for Merieux Developpement, with €220M under management. Isaac served as VP, Corporate Development at Synthetic Biologics, Inc. in 2016, and became CBO of HealthTell, leading its Merger concomitant with the spin-out of RubrYc in 2018.

This speaker's sessions: